MARKET

IMMP

IMMP

Immutep
NASDAQ
3.120
-0.110
-3.41%
Closed 18:48 05/22 EDT
OPEN
3.210
PREV CLOSE
3.230
HIGH
3.270
LOW
3.070
VOLUME
222.10K
TURNOVER
0
52 WEEK HIGH
3.335
52 WEEK LOW
1.580
MARKET CAP
370.92M
P/E (TTM)
-11.6331
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMMP last week (0513-0517)?
Weekly Report · 3d ago
Immutep Price Target Announced at $10.00/Share by Capital One
Dow Jones · 6d ago
Immutep Initiated at Overweight by Capital One
Dow Jones · 6d ago
Capital One Initiates Coverage On Immutep with Overweight Rating, Announces Price Target of $10
Benzinga · 6d ago
Buy Rating on Immutep’s Efti: Promising Oncology Treatment with Significant Market Potential
TipRanks · 6d ago
Immutep Announces Promising Cancer Trial Results
Immutep has revealed promising results from the safety lead-in phase of its AIPAC-003 breast cancer trial. The treatment combines Immutep’s soluble LAG-3 protein with paclitaxel. Further efficacy and safety data from the study are anticipated in 2024.
TipRanks · 05/16 11:27
Earlier: Immutep Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
Immutep is developing novel LAG-3 immunotherapies for cancer and autoimmune disease. Data from the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha in combination with paclitaxel.
Benzinga · 05/15 09:17
Weekly Report: what happened at IMMP last week (0506-0510)?
Weekly Report · 05/13 10:18
More
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.